Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | CHRND | Q07001 | 5/20 | 0.41 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.41 |
| ▸ | CHRNG | P07510 | 1/20 | 0.41 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 6/20 | 0.40 |
| ▸ | FURIN | P09958 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22593891 | 0.91 | TRPV1 (0.45) | CHRNDCHRNA1CHRNGCHRNB1GRIA1 | |
| SCHEMBL21782008 | 0.88 | CHRNB2 (0.44) | SIRT1SIRT2CHRNDCHRNA1CHRNG | |
| SCHEMBL22593905 | 0.87 | FURIN (0.36) | SIRT1SIRT2LMNAMAPTFURIN | |
| SCHEMBL22593908 | 0.86 | TRPV1 (0.46) | SIRT1SIRT2GRIA1 | |
| SCHEMBL19591557 | 0.85 | FURIN (0.49) | SIRT1SIRT2CHRNDCHRNA1CHRNG | |
| SCHEMBL22593910 | 0.84 | TRPV1 (0.46) | MAPT | |
| SCHEMBL25765429 | 0.82 | NPY5R (0.40) | SIRT1SIRT2 | |
| SCHEMBL24086378 | 0.82 | SPHK1 (0.49) | LMNAMAPT | |
| SCHEMBL22214485 | 0.82 | SIRT2 (0.46) | SIRT1SIRT2GRIA1 | |
| SCHEMBL16274143 | 0.81 | ROCK2 (0.44) | CHRNDCHRNA1CHRNGCHRNB1GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023002415-A2 | METHODS AND COMPOSITIONS FOR ANTI-CD117 ANTIBODY DRUG CONJUGATE (ADC) TREATMENT | Magenta Therapeutics, Inc. (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2020247670-A1 | METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASES | Magenta Therapeutics, Inc. (US) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020219748-A2 | ANTI-CD117 ANTIBODIES AND USES THEREOF | Magenta Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020146432-A1 | USE OF AN ANTI-CD45 ANTIBODY DRUG CONJUGATE (ADC) IN CELL THERAPY | Magenta Therapeutics, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020023559-A1 | USE OF AN ANTI-CD2 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | Magenta Therapeutics, Inc. (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2020023556-A1 | USE OF ANTI-CD137 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | Magenta Therapeutics, Inc. (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2020023561-A1 | USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | Magenta Therapeutics, Inc. (US) | 2020-01-30 | — | — | WO | disclosed |